Patient characteristics
| Variable . | Total . | Telomeres . | P . | |
|---|---|---|---|---|
| (n = 488), no. (%) . | No (n = 310), no. (%) . | Yes (n = 178), no. (%) . | ||
| Recipient sex, M/F | 291/197 (59.6/40.4) | 184/126 (59.4/40.6) | 107/71 (60.1/39.9) | .87 |
| Donor sex, M/F | 298/190 (61.1/38.9) | 191/119 (61.6/38.4) | 107/71 (60.1/39.9) | .74 |
| Donor/recipient sex mismatch | ||||
| F donor/M recipient | 105 (21.5) | 65 (21) | 40 (22.5) | .7 |
| Recipient median age, y (range) | 43 (5-68) | 44 (5-26) | 41 (6-68) | .11 |
| Patients <15 y | 31 (6.4) | 19 (6.1) | 12 (6.7) | .79 |
| Donor median age, y (range) | 34 (2-67) | 35 (2-66) | 33 (6-67) | .44 |
| CMV recipient, positive/negative/unknown | 268/210/10 (55/43/2) | 182/125/3 (26.4/40.3/1) | 86/85/7 (48.3/47.7/3.9) | .058 |
| CMV donor, positive/negative/unknown | 227/249/12 (46.5/51/2.5) | 154/149/7 (49.7/48.1/2.3) | 73/100/5 (41/56.2/2.8) | .07 |
| CMV R+/D− | 109 (23.2) | 68 (22.6) | 41 (24.3) | .086 |
| Disease | .17 | |||
| Acute leukemia | 211 (43.2) | 133 (42.9) | 80 (44.9) | |
| MPN | 42 (8.6) | 22 (7.1) | 20 (11.2) | |
| MDS | 52 (10.7) | 38 (12.3) | 14 (7.9) | |
| Lymphoma | 66 (13.5) | 47 (15.2) | 19 (10.7) | |
| Chronic lymphoproliferative disease | 59 (12.1) | 37 (11.9) | 22 (12.3) | |
| Other | 58 (11.9) | 33 (10.6) | 23 (12.9) | |
| Disease risk (ASBMT 2006) | .62 | |||
| Standard | 259 (53.1) | 163 (52.6) | 96 (53.9) | |
| High | 173 (35.5) | 114 (36.8) | 59 (33.1) | |
| Nonmalignant | 56 (11.5) | 33 (10.6) | 23 (12.9) | |
| HLA matching | .46 | |||
| Matched related | 251 (51.4) | 154 (49.7) | 97 (54.5) | |
| Matched unrelated | 182 (37.3) | 122 (39.4) | 60 (33.7) | |
| Mismatched unrelated | 55 (11.3) | 34 (11) | 21 (11.8) | |
| Stem cell source, BM/PBSC | 108/380 (22.1/77.9) | 67/243 (21.6/78.4) | 41/137 (23/77) | .72 |
| Conditioning regimen | .124 | |||
| MAC | 200 (41) | 119 (38.4) | 81 (45.5) | |
| RIC or sequential | 288 (59) | 191 (61.6) | 97 (54.5) | |
| ATG in conditioning | 175 (35.9) | 118 (38.1) | 57 (32) | .18 |
| Conditioning | .38 | |||
| MAC no TBI | 123 (25.2) | 71 (22.9) | 52 (29.2) | |
| MAC TBI 12 Gy | 77 (15.8) | 45 (15.5) | 26 (16.3) | |
| RIC no TBI | 184 (37.7) | 124 (40) | 60 (33.7) | |
| RIC TBI 2 Gy | 104 (21.3) | 67 (21.6) | 37 (20.8) | |
| GVHD prophylaxis | .121 | |||
| CsA/MTX | 211 (43.3) | 125 (40.3) | 86 (48.6) | |
| CsA/MMF | 263 (54) | 177 (57.1) | 86 (48.6) | |
| Other | 13 (2.7) | 8 (2.6) | 5 (2.8) | |
| Transplantation year | <10e-10 | |||
| 2006 | 62 (12.7) | 48 (15.5) | 14 (7.9) | |
| 2007 | 56 (11.5) | 22 (7.1) | 34 (19.1) | |
| 2008 | 61 (12.5) | 27 (8.7) | 34 (19.1) | |
| 2009 | 71 (14.5) | 67 (21.6) | 4 (2.2) | |
| 2010 | 89 (18.2) | 81 (26.1) | 8 (4.5) | |
| 2011 | 94 (19.3) | 59 (19) | 35 (19.7) | |
| 2012 | 55 (11.3) | 6 (1.9) | 49 (27.5) | |
| Ferritin | .54 | |||
| <2500 ng/mL | 236 (86.1) | 161 (87) | 75 (84.3) | |
| ≥2500 ng/mL | 38 (13.9) | 24 (13) | 14 (15.7) | |
| Missing data | 214 | 125 | 89 | |
| CRP | .77 | |||
| ≤9 mg/L | 339 (81.5) | 213 (81.9) | 126 (80.8) | |
| >9 mg/L | 77 (18.5) | 47 (18.1) | 30 (19.2) | |
| Missing data | 72 | 50 | 22 | |
| HCT-CI | .83 | |||
| 0 | 39 (8) | 26 (8.4) | 13 (7.3) | |
| 1 or 2 | 101 (20.7) | 62 (20) | 39 (21.9) | |
| ≥3 | 348 (71.3) | 222 (71.6) | 126 (70.8) | |
| Variable . | Total . | Telomeres . | P . | |
|---|---|---|---|---|
| (n = 488), no. (%) . | No (n = 310), no. (%) . | Yes (n = 178), no. (%) . | ||
| Recipient sex, M/F | 291/197 (59.6/40.4) | 184/126 (59.4/40.6) | 107/71 (60.1/39.9) | .87 |
| Donor sex, M/F | 298/190 (61.1/38.9) | 191/119 (61.6/38.4) | 107/71 (60.1/39.9) | .74 |
| Donor/recipient sex mismatch | ||||
| F donor/M recipient | 105 (21.5) | 65 (21) | 40 (22.5) | .7 |
| Recipient median age, y (range) | 43 (5-68) | 44 (5-26) | 41 (6-68) | .11 |
| Patients <15 y | 31 (6.4) | 19 (6.1) | 12 (6.7) | .79 |
| Donor median age, y (range) | 34 (2-67) | 35 (2-66) | 33 (6-67) | .44 |
| CMV recipient, positive/negative/unknown | 268/210/10 (55/43/2) | 182/125/3 (26.4/40.3/1) | 86/85/7 (48.3/47.7/3.9) | .058 |
| CMV donor, positive/negative/unknown | 227/249/12 (46.5/51/2.5) | 154/149/7 (49.7/48.1/2.3) | 73/100/5 (41/56.2/2.8) | .07 |
| CMV R+/D− | 109 (23.2) | 68 (22.6) | 41 (24.3) | .086 |
| Disease | .17 | |||
| Acute leukemia | 211 (43.2) | 133 (42.9) | 80 (44.9) | |
| MPN | 42 (8.6) | 22 (7.1) | 20 (11.2) | |
| MDS | 52 (10.7) | 38 (12.3) | 14 (7.9) | |
| Lymphoma | 66 (13.5) | 47 (15.2) | 19 (10.7) | |
| Chronic lymphoproliferative disease | 59 (12.1) | 37 (11.9) | 22 (12.3) | |
| Other | 58 (11.9) | 33 (10.6) | 23 (12.9) | |
| Disease risk (ASBMT 2006) | .62 | |||
| Standard | 259 (53.1) | 163 (52.6) | 96 (53.9) | |
| High | 173 (35.5) | 114 (36.8) | 59 (33.1) | |
| Nonmalignant | 56 (11.5) | 33 (10.6) | 23 (12.9) | |
| HLA matching | .46 | |||
| Matched related | 251 (51.4) | 154 (49.7) | 97 (54.5) | |
| Matched unrelated | 182 (37.3) | 122 (39.4) | 60 (33.7) | |
| Mismatched unrelated | 55 (11.3) | 34 (11) | 21 (11.8) | |
| Stem cell source, BM/PBSC | 108/380 (22.1/77.9) | 67/243 (21.6/78.4) | 41/137 (23/77) | .72 |
| Conditioning regimen | .124 | |||
| MAC | 200 (41) | 119 (38.4) | 81 (45.5) | |
| RIC or sequential | 288 (59) | 191 (61.6) | 97 (54.5) | |
| ATG in conditioning | 175 (35.9) | 118 (38.1) | 57 (32) | .18 |
| Conditioning | .38 | |||
| MAC no TBI | 123 (25.2) | 71 (22.9) | 52 (29.2) | |
| MAC TBI 12 Gy | 77 (15.8) | 45 (15.5) | 26 (16.3) | |
| RIC no TBI | 184 (37.7) | 124 (40) | 60 (33.7) | |
| RIC TBI 2 Gy | 104 (21.3) | 67 (21.6) | 37 (20.8) | |
| GVHD prophylaxis | .121 | |||
| CsA/MTX | 211 (43.3) | 125 (40.3) | 86 (48.6) | |
| CsA/MMF | 263 (54) | 177 (57.1) | 86 (48.6) | |
| Other | 13 (2.7) | 8 (2.6) | 5 (2.8) | |
| Transplantation year | <10e-10 | |||
| 2006 | 62 (12.7) | 48 (15.5) | 14 (7.9) | |
| 2007 | 56 (11.5) | 22 (7.1) | 34 (19.1) | |
| 2008 | 61 (12.5) | 27 (8.7) | 34 (19.1) | |
| 2009 | 71 (14.5) | 67 (21.6) | 4 (2.2) | |
| 2010 | 89 (18.2) | 81 (26.1) | 8 (4.5) | |
| 2011 | 94 (19.3) | 59 (19) | 35 (19.7) | |
| 2012 | 55 (11.3) | 6 (1.9) | 49 (27.5) | |
| Ferritin | .54 | |||
| <2500 ng/mL | 236 (86.1) | 161 (87) | 75 (84.3) | |
| ≥2500 ng/mL | 38 (13.9) | 24 (13) | 14 (15.7) | |
| Missing data | 214 | 125 | 89 | |
| CRP | .77 | |||
| ≤9 mg/L | 339 (81.5) | 213 (81.9) | 126 (80.8) | |
| >9 mg/L | 77 (18.5) | 47 (18.1) | 30 (19.2) | |
| Missing data | 72 | 50 | 22 | |
| HCT-CI | .83 | |||
| 0 | 39 (8) | 26 (8.4) | 13 (7.3) | |
| 1 or 2 | 101 (20.7) | 62 (20) | 39 (21.9) | |
| ≥3 | 348 (71.3) | 222 (71.6) | 126 (70.8) | |
ATG, anti-thymocyte globulin; BM, bone marrow; CsA, cyclosporine A; F, female; GVHD, graft-versus-host disease; M, male; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; MPN, myeloproliferative neoplasm; MTX, methotrexate; PBSC, peripheral blood stem cell; RIC, reduced-intensity conditioning; TBI, total-body irradiation.